======EXAMPLE RECOMMENDATIONS ASSESSMENT TABLE======
^Candidate Recommendation ^Interpretation/Justification Comments ^Ontario Context Comments ^New Evidence Likely? ^Assessment? (Endorse/Endorse with Changes/Reject) ^Clarifications/Qualifying Statements
|The routine use of adjuvant chemotherapy for all patients with stage II [TYPE] cancer is not recommended. |None |None |No |Endorse| None
|When treated with adjuvant therapy, high-risk stage II patients should receive [DRUG A] or [DRUG B]. |None |[DRUG A] is not yet funded in Ontario. |No |Endorse with Changes |Qualifying Statement: [DRUG A] is not currently funded in Ontario.
|Adjuvant chemotherapy with a [DRUG B] monotherapy regimen following surgery in patients who have [MARKER] is recommended. |The guideline authors overestimated the net benefit of [DRUG B] in the population for [REASONS]. |None |None |Reject |Replace with: At this time, there is insufficient evidence to recommend [DRUG B] in patients with [MARKER].

Back to the [[projectdev:cco_endorsement_protocol| the CCO Endorsement Protocol]]